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Despite the relevance of carbapenemase-producing Klebsiella pneumoniae (CP-Kp)
infections there are a scarce number of studies to evaluate in vivo the efficacy of
combinations therapies. The bactericidal activity of colistin, rifampin, and its combination
was studied (time–kill curves) against four clonally unrelated clinical isolates of CP-Kp,
producing VIM-1, VIM-1 plus DHA-1(acquired AmpC β-lactamase), OXA-48 plus CTX-
M-15 (extended spectrum β-lactamase) and KPC-3, respectively, with colistin MICs of
0.5, 64, 0.5, and 32 mg/L, respectively. The efficacies of antimicrobials in monotherapy
and in combination were tested in a murine peritoneal sepsis model, against all the
CP-Kp. Their efficacies were tested in the pneumonia model against the OXA-48
plus CTX-M-15 producers. The development of colistin-resistance was analyzed for
the colistin-susceptible strains in vitro and in vivo. In vitro, colistin plus rifampin was
synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin
alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-
M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two
CP-Kp and of the KPC-3 strain. Rifampin and the combination increased the survival
against the KPC-3 strain; in the pneumonia model, the combination also improved the
survival. No resistant mutants appeared with the combination. In conclusion, CMS plus
rifampin had a low and heterogeneous efficacy in the treatment of severe peritoneal
sepsis model due to CP-Kp producing different carbapenemases, increasing survival
only against the KPC-3 strain. The combination showed efficacy in the less severe
pneumonia model. The combination prevented in vitro and in vivo the development of
colistin resistant mutants.
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INTRODUCTION
Carbapenem-resistant Klebsiella pneumoniae strains are
spreading worldwide, representing an urgent threat to public
health, as stressed by the Center for Disease Control and
Prevention (CDC) of United States, the European Centre for
Disease Prevention and Control (ECDC) and the World Health
Organization (WHO). The rapid spread, mostly in hospital
settings, is transforming many common health care-associated
complications into infections that are sometimes untreatable
with the currently available antimicrobials (Nordmann et al.,
2012).
The carbapenem resistance in K. pneumoniae is mainly
due to the production of acquired carbapenemases (Falagas
et al., 2014). The most important carbapenemases found in this
species may belong to the Ambler classes A (mainly KPC), B
(the most frequent are VIM and IMP) and D (OXA-48-like
enzymes). Invasive infections by isolates producing VIM and
KPC are associated with high death rates (Tzouvelekis et al.,
2012). The information about infections caused by OXA-48-
producers is scarce, mostly because of its difficult identification
(Nordmann et al., 2011; Canton et al., 2012; Tzouvelekis et al.,
2012). Nevertheless, OXA-48 is the most frequent carbapenemase
produced by Enterobacteriaceae isolated in many European
countries (Canton et al., 2012; Palacios-Baena et al., 2016; De
Laveleye et al., 2017).
Although the hydrolysis spectrum of these enzymes may
vary, they hydrolyze most beta-lactams, including carbapenems.
Moreover, carbapenemase producers often show co-resistance
to other antimicrobial agents, leaving very few treatment
options, such as tigecycline, colistin, and some aminoglycosides
(de Oliveira et al., 2015). So, in an attempt to improve
the poor clinical efficacy of the available drugs, combination
therapy is often used as definitive therapy for infections
caused by carbapenemase-producing K. pneumoniae (CP-Kp).
To date, recommendations are based on few retrospective
clinical studies and in vitro studies (Tzouvelekis et al.,
2012). In addition, a scarce number of in vivo studies have
assessed the efficacy of antimicrobial combinations against CP-
Kp (Tzouvelekis et al., 2012). Clinical studies have reported
favorable outcomes for patients treated with combinations
of colistin and a carbapenem, tigecycline, fosfomycin, or
an aminoglycoside (Michalopoulos et al., 2010; Lee and
Burgess, 2012; Munoz-Price et al., 2013; Daikos et al., 2014).
However, little data exists on which combination therapy is
superior.
Several studies have reported synergistic activity of colistin
and rifampin against colistin-resistant and colistin-susceptible
KPC-producing K. pneumoniae clinical strains, using the
checkerboard method. Similarly, studies based on time-kill
experiments detected synergy with this combination against
colistin-resistant KPC or NDM producers clinical strains,
but no synergistic effect against VIM producers. To our
knowledge, there is no data regarding the efficacy of this
combination against K. pneumoniae producing OXA-48, nor
in vivo studies to validate the in vitro results previously
mentioned (Elemam et al., 2010; Tascini et al., 2013; Nastro
et al., 2014; Tangden et al., 2014). Thus, the aim of this study
was to evaluate the in vitro and in vivo efficacy of CMS
plus rifampin against CP-Kp clinical strains producing different
carbapenemases.
MATERIALS AND METHODS
Bacterial Strains, Beta-lactamase
Characterization and Molecular Typing
Four genetically unrelated clinical isolates of CP-Kp were
studied: Kp07, a VIM-1 ST 1603 clone producer (Miro et al.,
2013); Kp21, which co-produced VIM-1 and the acquired
AmpC type beta-lactamase DHA-1 ST 11 clone (Miro et al.,
2013); Kp28, co-producing OXA-48 ST11 clone and the
extended spectrum beta-lactamase (ESBL) CTX-M-15 (Oteo
et al., 2015); and Kp29, co-producing KPC-3 ST512 clone
with the broad spectrum beta-lactamases TEM-1 and SHV-11
(Lopez-Cerero et al., 2014), thereinafter VIM-1, VIM-1/DHA-
1, OXA-48 plus CTX-M-15, and KPC-3 producers, respectively.
Identification of these isolates was confirmed by a Microflex
LT-MALDI Biotyper mass spectrometer (Bruker Daltonics
GmbH, Bremen, Germany). The presence of carbapenemase
genes, and genes coding for other beta-lactamases was confirmed
by PCR and sequencing as described previously. The absence
of genetic relation among the isolates was confirmed by
PFGE analysis of chromosomal restriction fragments obtained
after XbaI cleavage following the criteria of Tenover et al.
(1995). Two of the strains, KPC-3 and VIM-1 (DHA-1) were
multidrug-resistant while the other two were not. The antibiotic
susceptibility profiles are included in the Supplementary
Information.
Antimicrobials
For the in vitro assays, antimicrobials, colistin sulfate salt
and rifampin, were used as standard laboratory powders
(Sigma-Aldrich, Madrid, Spain). For in vivo experiments,
clinical formulations were used: colistimethate sodium (CMS)
(Genéricos Españoles S.A., Madrid, Spain) and rifampin (Sanofi-
Aventis, Madrid, Spain).
In Vitro Studies
Antimicrobial Susceptibility Testing
MICs of antibiotics were determined by broth microdilution as
recommended by the Clinical and Laboratory Standards Institute
[CLSI] (2012), using Mueller Hinton broth II (MHB) (Becton
Dickinson & Co., Sparks, MD, United States) and agar dilution
method for fosfomycin. MIC results were interpreted according
to the European Committee on Antimicrobial Susceptibility
Testing [EUCAST] (2016)1 breakpoints. Studies were performed
in triplicate.
Time-Kill Curves
The concentrations of colistin used for susceptible strains
corresponded to the MIC value obtained by microdilution,
1http://www.eucast.org/clinical_breakpoints/
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whereas the concentration used for resistant strains was
2 mg/L, the susceptibility breakpoint recommended by European
Committee on Antimicrobial Susceptibility Testing [EUCAST]
(2016). Rifampin was used at a fixed concentration of 2 mg/L.
Experiments were carried out with a starting inoculum of
1 × 106 cfu/mL and the antibiotics alone or in combination.
Tubes were incubated at 37◦C, with shaking, and samples
were taken at 0, 1, 3, 6, and 24 h, serially diluted and
plated using a spiral platter (Eddy Jet, IUL S.A., Barcelona,
Spain). Bacterial colonies were counted using an automatic
counter (Flash & Go, IUL S.A., Barcelona, Spain) (Pournaras
et al., 2011; Souli et al., 2011). Experiments were performed
three times on separate occasions. Synergy was defined
as a decrease ≥ 2 log10 cfu/mL for the antimicrobial
combination compared with the most active single agent.
Bactericidal activities of single antibiotics or combination were
defined as a decrease ≥ 3 log10 cfu/mL from the starting
inoculum (Souli et al., 2009). Studies were performed in
triplicate.
Animals
Immunocompetent C57BL/6 female mice weighing
approximately 20 g (Production and Experimentation Animal
Center, University of Seville, Seville, Spain) were used; they
had a sanitary status of murine pathogen free and were
assessed for genetic authenticity. Mice were housed in an
individually ventilated cage system under specific pathogen-free
conditions, and water and food supplied ad libitum. This
study was carried out following the recommendations in the
Guide for the Care and Use of Laboratory Animals (Souli
et al., 2011). Experiments were approved by the Committee on
the Ethics of Animal Experiments of the University Hospital
Virgen Macarena, Seville, Spain (CI 1961). All procedures
were performed under sodium thiopental (B. Braun Medical
S.A., Spain) anesthesia, and all efforts were made to minimize
suffering.
Pharmacokinetic/Pharmacodynamic
Analysis
Serum antibiotic concentrations were determined in healthy
mice after a single intraperitoneal (ip) administration of
CMS (20 mg/kg) or rifampin (25 mg/kg). In sets of three
anesthetized mice, blood samples from the periorbital plexus
were obtained at different time points after the administration
of CMS and rifampin. Blood samples were immediately
centrifuged (4500 rpm, 15 min at 4◦C), and serum samples
stored at −80◦C until the analysis. Both serum free and total
antibiotic concentrations were measured using HPLC-tandem
mass spectrometry (LC-MS/MS) (Waters et al., 2008; Gobin et al.,
2010). Free fractions of the drugs were calculated as described
previously (Waters et al., 2008; Gonzalez et al., 2013; Cheah et al.,
2015).
Maximum concentration of drug in serum (Cmax), elimination
half-life (t1/2), area under the concentration-time curve from 0
to 24 h (AUC0−24), free AUC0−24 (fAUC0−24), AUC0−24/MIC
and fAUC0−24/MIC ratios were calculated using the PKSOLVER
program (Zhang et al., 2010). The pharmacodynamic targets to
assess the efficacy were fAUC0−24/MIC and AUC0−24/MIC for
CMS and rifampin, respectively.
Experimental Models
Peritoneal Sepsis Model
A previously described murine peritoneal sepsis model was used
(Parra Millan et al., 2016). Briefly, groups of un-anesthetized
C57BL/6 mice were infected by ip injection of 0.5 mL of the
Minimal Lethal Dose (MLD) of each strain, corresponding to
(log10 cfu/mL): 8.97, 8.94 9.35, and 8.38 for VIM-1, VIM-1/DHA-
1, OXA-48 plus CTX-M-15, and KPC-3 strains, respectively.
Treatments were initiated 4 h post-inoculation. For each
one of the strains, mice were randomly included into four
different therapeutic groups: (1) controls (untreated), (2) CMS,
20 mg/kg/8 h/ip, (3) rifampin, 25 mg/kg/6 h/ip, and (4) CMS plus
rifampin, using the same dosing schedule as in monotherapy. The
sample size for the combination groups and CMS monotherapy
for the colistin-susceptible strains (VIM-1 and OXA-48 plus
CTX-M-15) was 15 mice; nevertheless, for the monotherapies
in case of resistance to colistin (VIM-1/DHA-1 and KPC-3) and
for rifampin, the sample size was 10 to accomplish the 3Rs
(Replacement, Reduction and Refinement) rules for performing
animal research. Afterward, mice were treated and monitored for
72 h. The antimicrobial dosages were based on the PK/PD data,
and their proven efficacy, alone and in combination, in previous
experimental murine models of infection (Pachon-Ibanez et al.,
2010). Samples were extracted and processed immediately after
the death of mice; the survivor mice were sacrificed (sodium
thiopental) at the 72 h. Aseptic thoracotomies were carried
out, and blood samples were obtained for qualitative blood
cultures; results were expressed as positive (≥1 cfu present in the
plate) or negative. Spleens were aseptically extracted, weighed,
and homogenized in sterile saline (Stomacher 80; Tekmar Co.,
Cincinnati, OH, United States) before quantitative cultures (log10
cfu/g) in Columbia agar with 5% sheep blood plates.
Pneumonia Model
A previously characterized murine pneumonia model was used
(Pachon-Ibanez et al., 2010; Docobo-Perez et al., 2012; Parra
Millan et al., 2016) with the OXA-48 plus CTX-M-15 strain,
as OXA-48 is the most prevalent carbapenemase in Spain
nowadays (Palacios-Baena et al., 2016). Anesthetized mice were
infected intratracheally, using 50 µl of a final inoculum of 8.18
log10 cfu/mL. Therapies were initiated 4 h post-infection and
treatment groups and dosages were the same as in the peritoneal
sepsis model. Mice were treated and monitored over 72 h. After
death or sacrifice of the mice at 72 h, blood and lungs samples
were aseptically obtained and processed as detailed above.
In Vitro and in Vivo Selection of
Colistin-Resistant and
Rifampin-Resistant Mutants
Up to 10 colonies, of colistin-susceptible strains exposed during
24 h to colistin at the MIC, alone or in combination with
rifampin, in time-kill curves, and from controls (non-exposed to
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the antimicrobials), were sub-cultured twice in antimicrobial free
medium and frozen at−80◦C until MIC testing.
In the experimental murine pneumonia model, after
processing the lungs as described above, the remaining
homogenized tissue was vortexed and centrifuged, and the pellet
was resuspended in 2 mL of sterile saline. All the volume was
spread on agar and incubated for 48 h at 37◦C. A maximum of
ten colonies recovered from each lung were selected, sub cultured
in antibiotic free medium twice and frozen at −80◦C until MIC
testing.
MICs determinations of colistin and rifampin were carried out
in triplicate.
Statistical Analysis
Mortality and bacteremia rates are expressed as percentages and
bacterial tissue concentrations (log10 cfu/g) as means ± SD. The
two-tailed Fisher’s test, analysis of variance (ANOVA), and the
Dunnet and Tukey post hoc tests were used. A P < 0.05 was
considered significant. The SPSS v22.0 statistical package was
used (SPSS Inc).
RESULTS
In Vitro Results
Antimicrobial Susceptibility Testing
MICs of each antibiotic for the four clinical isolates are shown
in Table 1. Two strains were resistant to colistin (VIM-1/DHA-1
and KPC-3 producers).
Time-Kill Curves
The results are shown in Figure 1. Colistin was bactericidal at
3 h against the VIM-1 producer, but an important regrowth
at 24 h. In addition, colistin reduced bacterial concentration
(2.5 log10 decrease in cfu/mL) of the OXA-48 plus CTX-M-15-
producing isolate, again with an important regrowth at 24 h.
Colistin did not display any bactericidal activity against the
colistin-resistant isolates (VIM-1/DHA-1 and KPC-3 producers).
Rifampin did not show bactericidal activity against any strain.
The combination was synergistic against all the strains at 24 h,
but achieving only a bacteriostatic effect against the VIM-1,
VIM-1/DHA-1, and OXA-48 plus CTX-M-15 isolates; on the
contrary, the combination was bactericidal against the KPC-3
isolate.
TABLE 1 | MICs of colistin and rifampin for the four carbapenemase-producing
K. pneumoniae clinical strains.
Strains MIC (mg/L) [SIR]
Colistin Rifampin
VIM-1 0.5 [∗] 32 [∗∗∗]
VIM-1/DHA-1 64 [∗∗] >128 [∗∗∗]
OXA-48/CTX-M-15 0.5 [∗] 32 [∗∗∗]
KPC-3 32 [∗∗] 64 [∗∗∗]
∗Susceptible, MIC ≤ 2 mg/L. ∗∗Resistant, MIC > 2 mg/L. ∗∗∗Breakpoints are not
defined (intrinsically resistant).
Pharmacokinetics and
Pharmacodynamics
Pharmacokinetic parameters of each antimicrobial are
shown in Table 2. Pharmacodynamics profiles are shown
in Tables 3, 4.
In Vivo Results: Peritoneal Sepsis Model
The efficacies of the antimicrobials are shown in Table 3.
Mortality, bacterial clearance on spleen and bacteremia, are
analyzed immediately after the death of mice or at the end of the
experiment (72 h of treatment).
Mortality
Mortality in all control groups (non-treated) was 100% within the
first 24 h post-infection. Rifampin and its combination with CMS
reduced mortality in animals infected with the KPC-3 strain to
a 66.67% and a 40%, respectively, but not CMS alone. There was
no reduction of mortality with any treatment when the peritoneal
sepsis was produced by the other strains.
Bacterial Clearance From Spleen
Rifampin alone improved significantly the clearance of bacteria
from spleen (CFU/g of tissue) compared with the control and
the CMS groups in mice infected with either of the two colistin-
susceptible strains producing VIM-1 (7.14± 0.48 vs. 8.92± 0.46
and 7.14 ± 0.48 vs. 8.60 ± 0.30, respectively) or OXA-48 plus
CTX-M-15 (8.24 ± 0.76 vs. 9.56 ± 0.47, and 8.24 ± 0.76
vs. 9.52 ± 0.55, respectively). CMS plus rifampin reduced the
bacterial concentration compared with the controls for both
colistin-susceptible strains, producing VIM-1 or OXA-48 plus
CTX-M-15 and for the colistin-resistant strain producing KPC-
3, (6.01 ± 1.77 vs. 8.92 ± 0.46, 7.06 ± 2.50 vs. 9.56 ± 0.47,
and 6.76 ± 2.48 vs. 10.19 ± 0.29, respectively). The combination
was also better than CMS alone for both colistin-susceptible
strains (6.01 ± 1.77 vs. 8.60 ± 0.30, 7.06 ± 2.50 vs. 9.52 ± 0.55,
respectively).
Bacteremia
CMS plus rifampin showed the best effect among all the
treatment groups in sterilizing blood cultures of mice infected
with any of the four strains. Nevertheless, this reduction was only
significant in mice infected with the VIM-1 producer (53.33% vs.
100%).
Pneumonia Model Results
Table 4 summarizes the results for the pneumonia model.
Mortality
The severity of this model was lower, with a mortality of 40% at
the end of the experiment (72 h) using the MLD in the control
group. Only the combination therapy decreased significantly
mortality compared with the control group (6.26% vs. 40%;
P < 0.05).
Bacterial Clearance From Lungs
Rifampin alone and its combination with CMS decreased
significantly bacterial lung concentration compared with the
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FIGURE 1 | Time-kill curves for colistin (CST) and rifampin (RIF) alone and in combination against four clinical strains of carbapenemase producing strains (VIM-1,
VIM-1/DHA-1, OXA-48/CTX-M-15 and KPC3). The CST concentration used for colistin-susceptible strains corresponded to the value of their MICs (colistin 0.5 mg/L
for VIM-1 and OXA-48/CTX-M-15); for colistin-resistant isolates the concentration of CST was that corresponding to the susceptibility breakpoint recommended by
EUCAST (colistin 2 mg/L for VIM-1/DHA-1 and KPC-3). The RIF concentration used for all strains was 2 mg/L. RIF, filled circles; CST, filled squares; combination of
both antimicrobials, filled triangles.
control (3.07 ± 1.63 vs. 8.05 ± 2.36, and 2.99 ± 1.36 vs.
8.05± 2.36, respectively).
Bacteremia
None of the antimicrobial treatments achieved a significant
reduction of the bacteremia in comparison with the control
group.
In Vitro and in Vivo Selection of
Colistin-Resistant Mutants and
Rifampin-Resistant Mutants
Colistin MICs of colonies recovered from susceptible strains
(producing VIM-1 or OXA-48 plus CTX-M-15) after exposure at
the MIC during 24 h in time-kill curves increased from 0.5 mg/L
to> 8 mg/L. No mutants resistant to colistin were detected when
these strains were exposed to the combination of colistin plus
rifampin.
The MIC of rifampin for the colonies recovered from
the lungs of mice challenged with OXA-48 plus CTX-M-
15 producer and treated with rifampin alone increased from
16 to > 256 mg/L (16-folds) and the MIC of colistin from
the colonies recovered from the lungs of mice treated with
CMS as monotherapy increased from 1 to > 32 mg/L (32-
folds). Nevertheless, the MICs of rifampin and colistin remained
unchanged for those recovered from the control and the
combination group.
DISCUSSION
The results of this study show that CMS alone has no significant
efficacy in terms of bacterial clearance either from tissue and
blood or in the survival rate in the peritoneal sepsis model, even
in animals infected with strains susceptible to this antimicrobial.
To investigate whether these disappointing results were due to a
model effect, additional experiments were made in a less severe
murine pneumonia model using the strain producing OXA-
48 plus CTX-M-15. Once again, the bacterial lung and blood
concentrations as well as mortality were no different from those
TABLE 2 | Pharmacokinetic profiles of CMS and rifampin in mice serum.
Antimicrobial (dose
[mg/kg], route of
administration)
Drug Cmax (mg/L) t1/2 (h) AUC0−24
(mg·h/L)
CST (20, ip) tCST 2.87 3.82 13.65
fCST 0.24 3.82 1.15
RIF (25, ip) tRIF 72.58 19.33 1103.58
fRIF 2.90 19.33 44.14
CST, colistin; RIF, rifampin; ip, intraperitoneal; tCST, total colistin; fCST, free
colistin; tRIF, total rifampin; fRIF, free rifampin; ip., intraperitoneal; Cmax, maximum
concentration of drug in serum; t1/2, half-life; AUC0−24, area under the
concentration-time curve from 0 to 24 h; fAUC0−24, the unbound fraction
AUC0−24.
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TABLE 3 | In vivo efficacy and pharmacodynamics of CMS and rifampin, alone and in combination, for the experimental peritoneal sepsis model.
Strain Treatment group n Log10 cfu/g spleen
(mean ± SD)
Bacteremia (%) Mice mortality (%) AUC0−24/MIC∗ fAUC0−24/MIC∗
VIM-1 CTL 9 8.92 ± 0.46 100 100 NA NA
CST 15 8.60 ± 0.30 100 93.33 NA 2.30
RIF 8 7.14 ± 0.48a 100 100 34.50 NA
CST + RIF 15 6.01 ± 1.77a 53.33b 93.33 NA NA
VIM-1/DHA-1 CTL 10 9.46 ± 0.32 100 100 NA NA
CST 6 9.54 ± 0.34 100 100 NA 0.04
RIF 8 9.68 ± 0.09 100 100 8.60 NA
CST+RIF 15 7.64 ± 3.02 73.33 73.33 NA NA
OXA-48 plus
CTX- M-15
CTL 10 9.56 ± 0.47 100 100 NA NA
CST 15 9.52 ± 0.55 100 100 NA 2.30
RIF 10 8.24 ± 0.76c 100 100 34.50 NA
CST+RIF 15 7.06 ± 2.50c 87.67 73.33 NA NA
KPC-3 CTL 10 10.19 ± 0.29 100 100 NA NA
CST 8 9.19 ± 1.85 100 75 NA 0.02
RIF 9 7.20 ± 2.96 88.88 66.67d 17.20 NA
CST+RIF 15 6.76 ± 2.48d 77 40d NA NA
CTL, control (no antimicrobial treatment); CST, colistin; RIF, rifampin; cfu, colony-forming unit; AUC0−24, area under the concentration-time curve from 0 to 24 h;
fAUC0−24, the unbound fraction AUC0−24. ∗PD parameters were determined in healthy mice after CMS or rifampin injection. aP ≤ 0.02 compared to CTL and CST
groups. bP < 0.05 compared to CTL, CST, and RIF groups. cP < 0.05 compared to CTL and CST groups. dP < 0.05 compared to CTL group.
TABLE 4 | In vivo efficacy and pharmacodynamics of CMS and rifampin, alone and in combination, for the experimental pneumonia model.
Strain Treatment group n Log10 cfu/g lung
(mean ± SD)
Bacteremia (%) Mice mortality (%) AUC0−24/MIC∗ fAUC0−24/MIC∗
OXA-48 plus
CTX- M-15
CTL 15 8.05 ± 2.36 53.30 40 NA NA
CST 15 5.14 ± 3.78 40 26.70 NA 2.30
RIF 15 3.07 ± 1.63a 20 13.30 34.50 NA
CST+RIF 16 2.99 ± 1.36a 31.25 6.26a NA NA
CTL, control (no antimicrobial treatment); CST, colistin; RIF, rifampin; cfu, colony-forming unit, AUC0−24, area under the concentration-time curve from 0 to 24 h; fAUC0−24,
the unbound fraction AUC0−24. ∗PD parameters were determined in healthy mice after CMS or rifampin injection. aP < 0.05 compared to CTL group.
of the control group. We believe that these results are related
with the development of colistin resistance during the CMS
monotherapy found in the pneumonia model.
The CMS dosage used in this study has been proven
to be effective in several murine experimental studies using
clinical multidrug-resistant (MDR) Acinetobacter baumannii
strains susceptible to colistin (MIC = 0.5 mg/L) (Pachon-
Ibanez et al., 2010; Docobo-Perez et al., 2012; Parra Millan
et al., 2016). Nevertheless, when this CMS dosage was used
in a murine pneumonia model by a NDM-1-producing
K. pneumoniae clinical strain, CMS monotherapy was not
effective as we found in the present study (Docobo-Perez
et al., 2012). Similar results were reported by de Oliveira
et al. (2015) in a retrospective clinical study, observing
suboptimal efficacy of polymyxins in the treatment of KPC-
producing Enterobacteriaceae infections, even in combination
with imipenem or meropenem.
One possible explanation to the lack of efficacy found with
CMS alone, could be that the PD parameter predictive of colistin
efficacy, fAUC0−24/MIC ratio (Cheah et al., 2015), has been
described in infections caused by other Gram-negative bacilli,
such as Pseudomonas aeruginosa and A. baumannii. So, the
present results would suggest that the described fAUC0−24/MIC
values to achieve various magnitudes of bacterial killing in
these Gram-negative bacilli are not the appropriate for the
treatment of CP-Kp infections, even for isolates with the
same MIC values. However, in these studies the end-point to
define the fAUC0−24/MIC values predicting colistin efficacy
was to achieve a 2 log10 decrease in bacterial concentrations
in lungs or thigh, but not to evaluate the mice survival
rates.
Colistimethate sodium monotherapy did not reduce
significantly the bacterial lung and blood results or the survival in
the less severe pneumonia model by the strain producing OXA-
48 plus CTX-M-15. However, it is noteworthy that CMS achieved
a bacterial lung decrease of 2.91 log10 cfu/g, a value defined as
optimal for P. aeruginosa and A. baumannii (Cheah et al., 2015),
although the wide SD precluded the significance of these data.
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In addition, the results in the pneumonia model demonstrate
that the severity of the chosen animal model is important when
studying the efficacy of antimicrobial treatments. Thus, new
colistin fAUC0−24/MIC values have to be defined for CP-Kp
and, in our opinion, for the treatment of other Gram-negative
bacilli infections.
The activity of rifampin in monotherapy in the peritoneal
sepsis model was also limited, reducing only bacterial spleen
concentration compared to control and CMS groups, infected
with VIM-1 or OXA-48 plus CTX-M-15 strains, for which an
AUC0−24 h/MIC = 34.5, predictor of efficacy was achieved. In
the case of animals infected with the KPC-3 strain, rifampin
did not decrease significantly the bacterial load in spleen or
blood, but reduced the mortality. However, the survival mice
conditions suggested that if the experiment were longer than 72 h,
all animals included in this treatment group would have died
shortly after. Moreover, a huge increase in MIC of rifampin was
observed after rifampin in vivo monotherapy. In the less severe
pneumonia model by OXA-48 plus CTX-M-15 strain, rifampin
monotherapy increased significantly the bacterial clearing from
lungs and blood, and also increased the mice survival. The
efficacy of rifampin against other Gram-negative bacteria has
been showed in experimental pneumonia models in mice (Wolff
et al., 1999; Montero et al., 2004; Pachon-Ibanez et al., 2010,
2011). Nevertheless, rifampin alone cannot be an alternative due
to the generation of rifampin-resistant mutants (Pachon-Ibanez
et al., 2006).
Colistimethate sodium in combination with rifampin
demonstrated in vitro a synergistic effect against the four strains,
but the effect was bactericidal only against KPC-3 strain. These
results are in accordance with other studies showing synergy
of this combination against KPC-producing K. pneumoniae
strains. Nastro et al. (2014) reported a synergistic effect at 24 h
against 27 colistin-resistant KPC-2-producing K. pneumoniae
clinical strains. Similarly, Elemam et al. (2010) found synergy
with polymyxin B plus rifampin against 12 KPC-producing
K. pneumoniae clinical strains. Tascini et al. (2013) also
reported that CMS plus rifampin exhibited synergy against 13
colistin-resistant KPC-producing K. pneumoniae clinical strains,
moreover being bactericidal against the 62%. On the contrary,
in the case of K. pneumoniae producing VIM-1 the results of
the present study differ from those by Tangden et al. (2014),
where CMS plus rifampin did not exhibit synergy against two
colistin-susceptible VIM-1-producing K. pneumoniae clinical
strains.
With regard to the in vivo efficacy of CMS plus rifampin
in the experimental murine peritoneal sepsis model by the
colistin-susceptible VIM-1, the combination was better than
the control and CMS groups taking into account the bacterial
clearance from spleen and blood. When using the colistin-
susceptible OXA-48 plus CTX-M-15 strain, the combination
only reduced the bacterial spleen concentration. For these two
colistin-susceptible strains, CMS and rifampin achieved the
pharmacodynamic values described as optimal, fAUC0−24/MIC
and AUC0−24/MIC, respectively (Jayaram et al., 2003; Gumbo
et al., 2007; Landersdorfer et al., 2017). Nevertheless, is worth
mentioning that the efficacy of the combination for both
colistin-susceptible strains was not optimal, if we consider that
mortality rates remained 93.3 and 73.3%, respectively.
Against the colistin-resistant KPC-3 strain, this combination
reduced the bacterial spleen concentration and mortality, in
accordance with the in vitro synergy studies. Nastro et al.
(2014) reported a favorable outcome in five patients with
colistin-resistant KPC-2-producing K. pneumoniae infections
when treated with a combination of CMS plus rifampin. Against
the other colistin-resistant strain, producing VIM-1/DHA-1, this
combination was not efficacious, in contrast with the synergy
observed in the time-kill studies.
In the pneumonia model caused by the OXA-48 plus CTX-
M-15 strain, the activity of CMS plus rifampin was similar to
that of rifampin in monotherapy, decreasing the bacterial lung
concentration and increasing the mice survival compared with
the control group. This combination has been successfully used
against other Gram-negative bacilli (Pachon-Ibanez et al., 2010).
In this pneumonia model, the strain of K. pneumoniae developed
colistin resistance and a considerable increase in the MIC of
rifampin when used as monotherapies, which was prevented
with the combination. This prevention of colistin resistant
mutant with this combination have been reported previously as
in the in vitro study published by Rodriguez et al. (2010) in
which they proved that the association of colistin plus rifampin
was synergistic against heteroresistant A. baumannii isolates
and prevented the development of colistin-resistant mutants
(Rodriguez et al., 2010).
Limitations of the study have to be done, first that even though
we wanted to evaluate the in vitro and in vivo effect of colistin plus
rifampin combination against clonally unrelated clinical isolates
of K. pneumoniae producing other carbapenemases, the number
of the tested strains is low. Moreover, the less severe pneumonia
model was only performed with one of the strains, and we believe
it will be very interesting to do it with all of the strains.
In summary, the results obtained suggest that CMS plus
rifampin has a low and heterogeneous efficacy in the treatment
of severe infections, such as a peritoneal sepsis infection,
caused by different CP-Kp strains, increasing only the mice
survival in the infection caused by the KPC-3 strain. CMS
plus rifampin combination prevents in vivo the development of
mutants resistant to colistin. Because of the lack of available
alternatives for these colistin-resistant KPC-3-producing strains,
the combination of CMS and rifampin might be considered for
further evaluation. Moreover, this combination showed efficacy
in the less severe pneumonia model by the OXA-48 plus CTX-
M-15 strain. Finally, an optimal PD index value for CMS efficacy
needs to be defined for K. pneumoniae. Overall, the results
of the present study suggest that the efficacy of CMS plus
rifampin depends on the class of carbapenemase produced by
K. pneumoniae and on the severity of the infection.
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